Skip to content

Analysis of the efficacy and safety of dotiapramib in the treatment of HIV infection

Analysis of the efficacy and safety of dotiapramib in the treatment of HIV infection

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027656
Enrollment
Unknown
Registered
2019-11-23
Start date
2019-11-20
Completion date
Unknown
Last updated
2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

Case series:Dotiapramib tablets (contains 600 mg of abacavir sulfate, 300 mg of lamivudine and 50 mg of dotilavir sodium)

Sponsors

Chongqing Public Health Medical Treatment Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-60 years old, male and female; (2) the diagnosis meets the HIV / AIDS diagnosis standard of China AIDS diagnosis and treatment guidelines (2018 Edition), and the patient is confirmed as HIV-1 infected; (3) those who sign informed consent and voluntarily participate in clinical trials.

Exclusion criteria

Exclusion criteria: (1) pregnant women; (2) those who have participated in the clinical trials of HIV vaccine or taken other drugs that affect the test indicators within the past three months; (3) those who plan to use DTG / ABC / 3TC, but HLA-B * 5701 gene test is positive; (4) those who are definitely allergic to EFV; (5) received art before; (6) in the judgment of the researcher, there may be potential violation of the test compliance or any other situation affecting the safety and effectiveness evaluation.

Design outcomes

Primary

MeasureTime frame
HIVRNA;CD4;CD4/CD8;

Secondary

MeasureTime frame
ALT;AST;TBIL;CR;TG;

Countries

China

Contacts

Public ContactLi Mingjun

Chongqing Public Health Medical Treatment Center

1050523111@qq.com+86 15920964586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026